Phase 2 trial of talabostat in stage IV melanoma.

被引：0
作者：
Redman, BG
Ernstoff, MS
Gajewski, TF
Cunningham, C
Lawson, DH
Gregoire, L
Haltom, E
Uprichard, MJ
机构：
[1] Univ Michigan, Comp Canc Ctr, Ann Arbor, MI 48109 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Mary Crowley Med Res Ctr, Dallas, TX USA
[5] Emory Univ, Atlanta, GA 30322 USA
[6] Point Therapeut, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：727S / 727S
页数：1
相关论文
共 50 条
  • [21] Treatment of patients with inoperable stage III or stage IV melanoma. Societe francaise de dermatologie
    Guillot, B.
    Charles, J.
    Jeudy, G.
    Cupissol, D.
    Dupuy, A.
    Dutriaux, C.
    Gangloff, D.
    Magne, N.
    Mirabe, X.
    M'Sadek, A.
    Pracht, M.
    Sichel, C.
    Do Outeiro, G.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (6-7): : 413 - 422
  • [22] A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma.
    Aamdal, S.
    Dueland, S.
    Engebraaten, O.
    Owre, K.
    Dyrhaug, M.
    Trachsel, S.
    Gaudernack, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 460S - 460S
  • [23] Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma.
    Letsch, A.
    Scheibenbogen, C.
    Fluck, M.
    Asemissen, A.
    Nagorsen, D.
    Thiel, E.
    Keilholz, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 117S - 117S
  • [24] Phase II trial of carboplatin, paclitaxel and temozolomide in metastatic melanoma.
    Araujo-Mino, Emilio Paul
    Shaheen, Montaser F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Phase I trial of imatinib and temozolomide in patients with metastatic melanoma.
    Schuchter, L
    Flaherty, K
    Davidson, R
    Cavallaro, L
    Hendricks, M
    Deming, P
    Recio, A
    Tuveson, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
  • [26] A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.
    Alexandrescu, Doru T.
    Gonzales, Rene
    Lewis, Karl
    Samlowski, Wolfram
    Cranmer, Lee
    Catlett, Joseph
    Kirkwood, John
    Whitman, Eric
    Lawson, David
    Bartels, P.
    Drake, Terry
    Keating, Anne
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3385S - 3385S
  • [27] A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma
    Hodi, F. S.
    Friedlander, P. A.
    Atkins, M. B.
    McDermott, D. F.
    Lawrence, D. P.
    Ibrahim, N.
    Wu, X.
    Zhou, J.
    Giobbie-Hurder, A.
    Murphy, G.
    Hollman, T.
    Velazquez, E.
    Russell, S.
    Dipiro, P.
    Yap, J. T.
    Van den Abbeele, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] SAFETY AND EFFICACY OF INTRATUMORAL IPILIMUMAB WITH IV NIVOLUMAB IN METASTATIC MELANOMA. THE NIVIPIT TRIAL
    Tselikas, Lambros
    Robert, Caroline
    Dalle, Stephane
    Meyer, Nicolas
    Lebbe, Celeste
    Ammari, Samy
    Danlos, Francois-Xavier
    Roy, Severine
    Jannin, Camille
    Farhane, Siham
    Mourad, Severine
    Escriou, Guillaume
    Raoult, Thibault
    Scoazec, Jean-Yves
    Texier, Matthieuu
    Chaput-Gras, Nathalie
    Zitvogel, Laurence
    De Baere, Thierry
    Marabelle, Aurelien
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A300 - A300
  • [29] Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase Ill trial in patients with stage IIIb-IV melanoma.
    Ross, Merrick I.
    Andtbacka, Robert Hans Ingemar
    Puzanov, Igor
    Milhem, Mohammed M.
    Collichio, Frances A.
    Delman, Keith A.
    Noyes, R. Dirk
    Zager, Jonathan S.
    Cranmer, Lee D.
    Spitler, Lynn E.
    Hsueh, Eddy C.
    Ollila, David W.
    Amatruda, Thomas
    Chen, Lisa
    Gansert, Jennifer L.
    Kaufman, Howard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma.
    Richards, J.
    Testori, A.
    Whitman, E.
    Mann, G. B.
    Lutzky, J.
    Camacho, L.
    Parmiani, G.
    Hoos, A.
    Gupta, R.
    Srivastava, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 453S - 453S
12345